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Introduction
When a human infant is born prematurely, they are unable to receive the adequate
nutrient and mineral requirements from parenteral or enteral sources that would have been
provided to them in most intrauterine states. Preterm infants have low birth weights as the
majority of fetal weight gain occurs in the third trimester. Term infants can also be growth
restricted at birth for reasons pertaining to placental challenges such as pregnancy induced
hypertension, arterial venous anastomosis as in to twin transfusion syndrome, or when severe
maternal malnutrition exist. While not necessarily preterm, the products of these gestations will
need similar nutritional supplementation for growth and healthy neurodevelopment as the
preterm infant. The goal of many neonatal advanced practice nurse providers is to maintain
growth rates similar to the uterine environment and often times in the face of critical illnesses or
challenges. When adequate nutrition is not administered, extra-uterine growth restriction occurs.
Growth restriction has been directly correlated to the decreased structure and function of the
central nervous system, specifically when the restriction is during critical periods development
such as the neonate period. The central nervous system deficits are irreversible (Ziegler, 2011).
Growth goals that have been established for the preterm neonatal period is a weight gain of 15
g/kg/day, occipital frontal circumference growth of 0.5cm/week and length increases of 1
cm/week (Georgieff, 2005). The ability for a preterm infant to grow and have similar organ
development at intrauterine rates requires they receive increased amounts of protein, fat, and
minerals when compared to newborn term infants. To establish these goals, daily protein intake
should be 3.4-4.2gm/kg/day and caloric intake of 110-135kcal/kg/day, with the degree of
prematurity directly indicating nutritional needs on the higher side (Arslanoglu, Moro, & Ziegler,
2010). In addition to monitoring weekly measurements of preterm infants, serum lab work can be
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useful as indicators for growth and used to guide fortification of feedings. Serum sodium,
chloride, calcium and phosphorus requirements are necessary to monitor as the premature infant
will quickly develop defects following umbilical cord clamping exacerbated by their immature
kidney functioning. Trends in prealbumin, BUNs, and alkaline phosphate levels are also used as
indicators of protein status and markers of bone health respectively. Extra-uterine growth
restriction has a direct correlation to neurodevelopment challenges and is therefore an area of
importance to providers caring for these vulnerable infants. Excluding parenteral nutrition, the
ways in which neonatal care units provide growth restricted infants these requirements are by
enteral administration via a naso/orogastric tube of own mother’s breast milk (OMM), donor
breast milk (DBM), and preterm formulas (PF).
Human Milk
The literature supports improved neurodevelopment, cardiovascular health, and decreased
risks of cancer and other infectious incidences when infants are breastfed or provided OMM
(Gomella, 2009 and Arslanoglu, 2010). The properties of human milk (HM) that make it superior
for immunologic protection and developmental benefits include live cells, enzymes, and immune
factors (Georgieff, 2005). In addition to immunologic properties, HM is higher in fat than PF, a
benefit for premature infants, but low in protein and sodium which are both essential for the
somatic growth of premature infants. Pumped HM is also considered an inexpensive option for
families and health care systems.
OMM produced from mothers of preterm infants and term infants differs in its nutritional
qualities. The mother of an infant delivered preterm produces milk that has a higher content of
protein, chloride and sodium for the first 1-2 weeks, up to the first month postpartum. This richer
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preterm HM is a natural fortification for the underdeveloped neonate (Zeigler, 2011 & Gross,
David, Bauman, & Tomarelli, 1980).
Donor milk
Multiple sources state the majority of breast milk donated to milk banks is from mothers
of term infants (Lindemann, Foshauge, & Lindemann 2004); therefore, the widely accepted
assumption is the protein content is not adequate to sustain or grow a preterm infant as it is from
term mothers. While OMM has a variable amount of protein content regardless of the mother’s
gestiation, DM is “less variable, but lower in protein content” than any OMM (Zeigler, 2011). In
addition to the differences of preterm milk and term milk, protein content also decreases
throughout the course of lactation (Arslanoglu, Moro, & Ziegler, 2010), therefore donors who’s
own infants are now four or five months old will produce a less nutrient rich milk. DM also
undergoes a process OMM does not which is a pasteurization process, most often Holder
pasteurization. Holder pasteurization is the heating of milk to 62.5 degrees Celsius for 30
minutes. DM is then cultured and frozen to -20 degrees Celsius before being dispensed (Human
Milk Banking of North America, 2011). Human milk oligosaccharides and long-chained
polyunsaturated fatty acids are two immune factors that are maintained in DM throughout Holder
Pasteurization process (Bertino et al., 2008). Human milk oligosaccharides work with the
immune system and are responsible for prebiotic functioning and protection of intestinal
infections and long-chained polyunsaturated fatty acids assist with immunological protection of
the gastrointestinal track (Arslanoglu, Ziegler, & Moro, 2010). While these factors are
maintained, fractions of many immunologic factors such as sIgA, IgA, lactoferrin, lysozyme,
lymphocyte, lipase, and alkaline phosphatase are lost in the intense heating process. While not
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utilized as frequently and less studied, a shorter pasteurization process exists which is heating to
72 degrees Celsius five times, each time for 15 seconds (Heiman & Schanler, 2006).
Processes are in place and regulated in an attempt to ensure the safety of DM. Donors of
milk are routinely tested for cytomegalovirus, HIV, and Hepatitis B and C before donating and
throughout the process to confer safety for the already immuno-suppressed preterm infant who
will receive the DM. The possibility for viral transmission exists even if the donor serum is
negative at the time of donation. Finally, the process of pasteurization presents possible bacterial
contamination of DM, therefore all samples are cultured for colonization prior to distribution
(Lindemann, Foshaugen, & Lindeman, 2003).
Fortification
All HM, OMM or DM, is inadequate in the amounts of nutrients for the premature infant.
Standard practice is to fortify HM with human milk fortifier (HMF) when enteral feedings have
been advanced to 100ml/kg/day. HMFs, currently extracted from cow’s milk, contain protein,
carbohydrates, fats, and essential vitamins and minerals which afford providers the ability to
keep volumes of feedings in a range of 150-160ml/kg/day (Zeigler, 2011). Current research is
ongoing for the development of an HMF from human milk called Prolacta.
Gut Maturation and Necrotizing Enterocolitis
Preterm infants are not born with mature intestinal tracks, necessitating the need for slow
advancements in enteral feedings along with the use of total parenteral nutrition. Throughout the
history of neonatology, feedings were withheld and advanced slowly as the risk of necrotizing
enterocolitis (NEC) was realized (Zeigler, 2011). NEC is an inflammatory process of the bowel
in response to an intolerance of a substrate in the bowel lumen for reasons still unknown to
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providers. The bowel wall becomes damaged and, in severe stages, perforates leaking intestinal
contents into the peritoneum, a life threatening event. The field of neonatology now agrees the
way to mature the gut, increase motility, and promote microbial properties is to provide small
amounts of HM, OMM or DM consistently for the first few days to a week to prime the intestinal
track. These small feedings, called trophic feedings, are not utilized by the baby as essential
nutrition and parenteral nutrition continues to be utilized for administration of protein, fats, and
essential minerals. The immunologic properties of fresh OMM are absorbed by the infant’s
mucosal track which is called passive immunity, something pasteurized milk is less able to do
secondary to decreased amounts of IgA. Benefits of trophic feedings with OMM are two-fold,
intestinal maturity and immunologic protection.
DM is widely used by neonatal care units when OMM is unavailable and before PF is
considered as the risk of NEC is higher for premature infants receiving PF. Infant receiving DM
who are born on the edge of viability will receive DM for up to 6-8 weeks before they are
switched to PF around 32 to 34 weeks postmenstral age. This makes them vulnerable to the
negative neurodevelopment effects of extra-uterine growth restriction. The increasing usage of
DM necessitates an in-depth understanding regarding the benefits and consequences of its use. A
literature search on the subject of DM for optimal growth of preterm infants was surprising as
current research on the topic was limited. This lack of substantiated evidence in the literature
suggests the side effects of DM many not be fully realized by providers and necessitates the need
for further studies.
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Literature Review
In a randomized control trial published in 2005, Schanler et al. compared infants under 30
weeks gestation receiving exclusively OMM and infants who were supplemented with DBM or
PF when OMM was not available. A wide variety of short term outcome data were analyzed
including length of stay (LOS), infectious rates, including NEC, growth rates, and rates of skin to
skin contact between the mother and infant. To clarify, all subjects received some amount of
OMM, which was a limitation of this study because it is not clear how much OMM the subjects
received before being supplemented. The results could be confounded as the protective benefits
of OMM hid some outcome effects of the supplementation; however, the authors do point out the
amount of OMM received was not statistically different between the DM and PF groups. When
the control group, exclusive OMM, was compared to the DM and PF groups, infection rates were
improved, including decreased incidences of NEC, fewer gram negative cultures, shorter LOS,
and less severe staging of ROP rates, supporting common opinion that OMM is best for
premature infants. Another important factor the authors point out is the similar characteristics of
the subjects’ mothers who provided enough OMM. They were older, had a higher SES, and
visited their infant more, perhaps a confounding variable of the health of their infant regardless
of the supplementation use for enteral feedings. When DM was compared to PF there were no
differences in outcomes of NEC, LOS, or death. Slower weight gain was noted in the DM group.
This difference was so drastic, the principle investigator along with the attending neonatologists
switched 17 infants from the DM group to the PF before the end of the study. No difference in
OFC occurred throughout the three groups, however both DM and PF groups lagged behind
OMM group for length. It was also noticed that DM group needed higher sodium
supplementations and both the DM and PF groups needed higher oil or protein supplements
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when compared to the control OMM group. In the study design, the authors point out Enfamil
Human Milk Fortifier and Similac Human Milk fortifiers (likely the hospital contract changed
mid-study) are added to the OMM and the DM when the infants reached 100ml/kg/day of
feeding volume. The PF used was Enfamil Premature Formula, also specialized for premature
requirements. The DM was pumped from mothers of premature infants. This is an interesting
difference as most studies on DM do not specify the characteristics of the mother donating. Some
milk banks do keep DM pumped from mothers of preterm infants separate and sell it to hospitals
as preterm DM. This only seems to legitimize the results of this study further. Perhaps making
this a more thorough study would be inclusion of serum markers of growth between the two
groups.
In a prospective observational study of infants born under 32 weeks gestation, researchers
compared the growth of infants fed <20% OMM, more than 80% OMM, and those fed 20-80%
OMM with the supplementation being DM. Standard fortification was used for both OMM and
DM when feedings reached 100ml/kg/day. Using statistical significance values of p <0.05,
results indicated a mean weight gain of 5.1g/kg/day lower for infants fed less than 20% OMM.
Infants receiving 20-80% OMM had growth rates of 4.8g/kg/day lower and those fed >80%
OMM reached growth rates similar to intrauterine amounts of 15gm/kg/day. While this was a
small, single hospital study, without randomization and minimal controls, it does show results
consistent with other studies. The conclusion was properties of DM were insufficient to grow
premature infants at intrauterine rates (Montjauz-Régis, Cristini, Glorieux, Vanpee, and Casper,
2010).
A meta-analysis of seven studies, five of which were randomized control trials, were
reviewed to compare the use of OMM, pasteurized DM, and PF for outcomes of death, NEC,
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infection and growth for premature and growth restricted infants. True meta-analysis was not
possible as the outcome variables for growth were not standardized across the studies. For the
trials evaluating growth, it was concluded that there was a tendency for improved early postnatal
weight gain, increased OFCs, and skin fold thickness, but no gains in length for those fed
formula. Three of the studies evaluated the risk of NEC and concluded presumed cases of NEC
were not statistically significant; yet, confirmed rates of NEC were statistically lower for subjects
fed DM compared to PF. A combined risk difference of the 3 studies was determined to be 5.4%,
meaning 18.5 premature infants would need to be given donor milk instead of formula to prevent
one case of NEC. While this is a recent review, the studies were published in the 1970s and
1980s which is problematic as the field of knowledge for nutrition in neonatology has improved
since that time. The studies that evaluated DM did not include DM that was fortified with HMF,
a practice now standard. Thus interpretation of results must be done carefully when comparing
unfortified DM to PF. Another important factor to consider is the variable outcome criteria for
the studies used, making analysis difficult (Boyd, Quigley, & Brocklehurst, 2007).
A Cochrane database review compared DM to PF to evaluate growth of premature infants
and low birth weight infants, born less than 37 weeks gestation and weighing less than 2.5kg at
birth respectively. Studies included eight randomized controlled trials, including Schanler, et al.
from 2005 as outlined previously in this paper. Schanler et al. remains the only study to date
comparing fortified DM to formula, the others use unfortified DM. Schanler et al. is also the
only study within the last decade, all others included in this analysis were from the 1970 and
1980s. This meta-analysis concluded short term growth rates were higher for those fed formula
verses DM. Long term outcome data was analyzed and failed to show a difference in growth

DONOR BREAST MILK FOR PRETERM GROWTH: HELPFUL OR HURTFUL

10

rates or neurodevelopment outcome. This analysis indicated the incidence of NEC is statistically
increased in those fed formula over DM (Quigley, Henderson, Anthony, & McGuire, 2008).
Implications
The trials frequently cited in the literature, excluding one, are considered dated material
in modern neonatology, specifically with the changes in nutrient goals for premature infants.
Proponents of DM may argue that growth rates and development will not matter if the infant
suffers mortality secondary to NEC and therefore argue that OMM and DM are the only suitable
options for premature infants. However, as stated in the meta-analysis by Boyd and colleagues,
18.5 infants will need to receive DM to save one from death due to NEC. This risk-benefit can
be a difficult for providers to weigh. Rather, the practice should perhaps be to give all infants
OMM or DM through the first 14 days of life or first 14 days of feedings, when NEC is most
likely to occur and then switch to PF to focus energies on growth and development of the infant.
This increases the number of infants exposed to DM, something some parents may not feel
comfortable with and choose to withhold consent. Again, these conclusions are based on studies
that, for the most part, are decades old. It is clear more randomized control trials need to take
place before widespread recommendations are given. Currently, multiple neonatal intensive care
units are shifting towards increased usage and longer duration of DM feedings when OMM is not
available. In addition to the increased cost on the already stressed healthcare system, it is
puzzling since the literature review suggests it may not be the liquid silver (OMM being the
liquid gold) some believe it to be. Other options for the continued use of DM for this population
would be to target fortification individually; meaning all milk is tested for its protein, fat and
energy content and fortification is specialized to the individual neonate. Currently, serum
markers of protein status such as BUN, albumin and prealbumin are evaluated and a standard
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assumption of the qualities of DM is used. Again, this is a labor intensive activity and likely a
further expense on an already taxed system. If perfection remains what providers strive for, this
is the next modification.
Feeding low birth weight premature infants is a challenging task for the neonatal nurse
practitioners responsible for guiding the care of such infants. Forming a partnership with parents
is vital for open communication and education surrounding this topic. Honest communication
with families regarding feedings and the possible morbidities that threaten preterm infants is
essential. Advance practice nurses have the potential to encourage and support maternal pumping
of milk. Some situations can preclude the amount of OMM available, regardless of maternal
intent to provide, including maternal illness, medications, or breast tissue damage and must be
approached with support, sensitivity and care and without judgment. This is a challenging task,
but one neonatal nurse practitioners are capable of. It is essential all families are given all the
information regarding feeding their premature infants so they are able to make informed
decisions as partners in the care of their infants.
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